Hologic (HOLX) has been gaining from new strategic product launches across Diagnostics and Breast Health. However, macroeconomic issues and unfavorable FX headwinds continue to impede growth. The stock carries a Zacks Rank #3 (Hold) currently. Major Factors Driving HOLX Stock Growth Among Hologic's advanced diagnostic products, primary revenue-generating ones are molecular diagnostic assays, which run on advanced instrumentation systems (Panther, Panther Fusion and Tigris), ThinPrep cytology system and the ...

Hologic, Inc.'s (HOLX) sustained momentum in the Molecular Diagnostics portfolio is poised to fuel its growth in the upcoming quarters. A crucial part of its long-term strategy, the company is planning to expand into more countries overseas, which are largely untapped. It is also using its strong cash position strategically by focusing on acquisitions and share buybacks. Meanwhile, concerns remain over the impact of macroeconomic challenges on Hologic's operations. Adverse currency impact also adds to the w ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both. Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor. It also includes access to the Zacks Style Scores. What are ...

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both. The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens. Zacks Premium also includes the Zacks Style Scores. What are the Zacks Style Scores? Developed ...

Shares of Hologic (HOLX) are showing impressive gains of late, trading quite near its 52-week high of $84.67. The stock closed Thursday at $80.99, just 4.3% below the highest point. In the past three months, the women's health company's stocks have gained 8.5%, surpassing the industry's growth of 2% and the S&P 500's return of 2.8%. Hologic has also performed better than the industry rivals QIAGEN (QGEN) and Becton, Dickinson and Company (BDX) . Image Source: Zacks Investment Research 3-Months Performance T ...

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both. The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens. Zacks Premium also includes the Zacks Style Scores. What are the Zacks Style Scores? Developed al ...

Hologic, Inc.'s (HOLX) robust strength in the molecular diagnostics business places it well for growth in the upcoming quarters. The company's Breast Health franchise is now more diverse with the newest acquisition. Sound financial stability also bodes well. Meanwhile, the impact of macroeconomic conditions and adverse currency fluctuations remain a concern for Hologic's operations. In the past year, this Zacks Rank #3 (Hold) stock has rallied 8.2% compared with the 11.8% growth of the industry and a 26.3% ...

Women's health innovator, Hologic (HOLX) , reported third-quarter fiscal 2024 results on Jul 29 after market close. Revenues exceeded both the company's internal forecasts and the Zacks Consensus Estimate. The bottom line topped the consensus mark, although the extent of surprise lowered by nearly 37% than the previous quarter. Additionally, the ongoing supply headwinds in the company's Skeletal Health business factored into narrowed EPS guidance for the year. Following the earnings release, the stock rose ...

(1) See accompanying notes. | --- | --- | --- | --- | |-----------------------------------------------------------------------------------------------------------------------------|-------|---------------------------------|------------------------| | | | Nine Months \nJune 29, 2024 | Ended \nJuly 1, 2023 | | OPERATING ACTIVITIES | | | | | Net income | $ | 610.9 $ | 365.4 | | Adjustments to reconcile net income to net cash provided by operating activities: | | | | | Depreciation | | 75.2 | 66.7 | | Amortizat ...

Hologic, Inc. (HOLX) reported adjusted earnings per share (EPS) of $1.06 in the third quarter of fiscal 2024, up 14% year over year. The bottom line surpassed the Zacks Consensus Estimate by 3.9%. The adjustments include charges and benefits related to the amortization of acquired intangible assets, restructuring and integration/consolidation costs, product line discontinuation and many others. The company's GAAP EPS was 82 cents in the quarter compared to the year-ago quarter's loss of 16 cents. Revenues i ...